- UroGen Pharma ( NASDAQ: URGN ) stock rose ~4% on Sept. 28 after the company said that the U.S. Food and Drug Administration (FDA) authorized an extension of the in-use period for Jelmyto (mitomycin) for pyelocalyceal solution admixture from 8 hours to 96 hours after reconstitution of the product.
- Jelmyto is used to treat low-grade, upper-tract urothelial cancer (LG UTUC).
- "This extension expands access to JELMYTO and gives our customers greater flexibility in choosing when to mix and schedule instillations," said UroGen Chief Commercial Officer Jeff Bova.
For further details see:
UroGen gets FDA nod for extending duration of Jelmyto admixture